Ralph Niven, CHIEF SCIENTIFIC OFFICER at Aerovate Therapeutics, Inc. (AVTE), sold 4,600 shares at $18.67 ($88K) on 2024-01-05, disclosed to the SEC on 2024-01-08.
Scheduled sale ($88k) by CHIEF SCIENTIFIC OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $18.67 | 2,126 | $40K | 45.0% |
| 2 | $19.57 | 2,474 | $48K | 55.0% |
| Total | $19.15 avg | 4,600 | $88K | 100% |
| Filing → |
| AVTE | SELL | 2023-11-27 | $207K | — | Filing → |
| AVTE | SELL | 2023-07-07 | $39K | — | Filing → |
| AVTE | SELL | 2023-06-07 | $37K | — | Filing → |